CAR T-Cell survivors: what happens years later?
NCT ID NCT07048535
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 80 children and young adults who received CAR T-cell therapy for B-cell acute lymphoblastic leukemia (B-ALL) at least two years ago. Researchers want to see how feasible it is to track their long-term health, including any new or lasting side effects, brain function, immune health, and quality of life. Participants must be in remission and have had no other treatments after CAR T-cells (except a stem cell transplant). The goal is to better understand the lasting effects of this therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD19-directed CAR T-cell therapy
- What this could lead to
- If successful, this study could reveal the long-term health outcomes and quality of life after CAR T-cell therapy, helping doctors better manage survivors.
- What could go wrong
- This is an observational follow-up study, not a treatment trial. It may not lead to new therapies, and results depend on participant willingness to return for assessments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can antibody infusions outperform antibiotics in shielding CAR-T patients from infections?
- Can targeted drugs blinatumomab and venetoclax improve outcomes for childhood leukemia?
- Leukemia treatment may erase vaccine protection—study tests if re-vaccination works
- New cell therapy JY231 targets tough leukemia in early human test
- New CAR T-Cell therapy shows promise for kids with tough leukemia
- Experimental cell therapy targets tough blood cancers and anemia